Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
RESEARCH TOOLSreports
Centessa Pharmaceuticals (CNTA) Stock Price & Analysis
68 Followers
CNTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.96 - $12.45
Previous Close$9.4
Volume233.50K
Average Volume (3M)377.22K
Market Cap
$928.48M
Enterprise Value$730.16M
Total Cash (Recent Filing)$281.34M
Total Debt (Recent Filing)$83.02M
Price to Earnings (P/E)-6.0
Beta0.12
Next Earnings
May 13, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding100,305,850
10 Day Avg. Volume366,472
30 Day Avg. Volume377,218
Standard Deviation0.18
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.13
Forecast
1Y Price Target
$13.00Price Target Upside44.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Centessa Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsSerpinPC has displayed excellent safety and effectiveness in clinical trials, suggesting it may outshine its competitors in the hemophilia treatment market.
Financial HealthCNTA's unexpected revenue from out-licensing its CBS004 program demonstrates potential for future financial gains through milestone payments and royalties.
Regulatory ApprovalThe FDA's clearance for ORX750 to initiate Phase 1 trials represents a significant step forward in the drug's development process.
Bears Say
Competitive SetbacksDespite dose reductions, fitusiran continues to show thrombosis instances, potentially decreasing its efficacy.
Drug Safety ConcernsFDA's maximum exposure limit for ORX750 is based on convulsions observed in a canine study, which could raise concerns about its safety.
Efficacy ChallengesALKS2680 efficacy may be limited by the saturation of PK at ~15mg dose.
---
Ownership Overview
31.32% Insiders
6.72% Mutual Funds
24.24% Other Institutional Investors
37.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $3.96 and its highest was $12.45 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Currently, no data Available
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is May 13, 2024 which is in 17 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on Mar 28, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.488 by $0.108.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -$0.43.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 100,305,850 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.488. Following the earnings report the stock price went down -1.947%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Among the largest hedge funds holding Centessa Pharmaceuticals’s share is Platinum Investment Management. It holds Centessa Pharmaceuticals’s shares valued at 3M.
---
Centessa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (44.77% Upside)
$13.00 (44.77% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 263.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 23.8%
Last 30 Days ▼ 23.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.90%
12-Months-Change
Fundamentals
Return on Equity
-53.01%
Trailing 12-Months
Asset Growth
-18.31%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
---
CNTA Stock 12 Months Forecast
Average Price Target
$13.00
▲(44.77% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Arvinas Holding Company
―
BeiGene
―
Crispr Therapeutics AG
―
Best Analysts Covering CNTA
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+32.67%
assigned a buy rating 4 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +32.67% per trade.
---